New Crown Vaccine | News: Kexing promises to submit clinical data to Hong Kong government experts for review before publishing medical journals

Social News

Written by: Zhang Meilan

2021-02-05 17:56

The last update date: 2021-02-05 17:56

The new crown pneumonia vaccine is expected to be introduced to Hong Kong in March. The mainland Kexing vaccine ordered by the government has not been approved by the authorities for emergency use. The checkpoint is that Kexing has not yet submitted the data.

According to a source familiar with government vaccine procurement, Kexing has promised to submit the data to the World Health Organization and other regulatory authorities before publishing the academic report to the expert committee of the Hong Kong Department of Health and the Vaccine Advisory Expert Committee. discuss.

According to the news, the Department of Health is not the “back door” that refuses to review the data submitted by Kexing. It also reiterated that the procurement contract stipulates that the third-phase clinical data of the vaccine must be published in medical journals.

Kexing Vaccine has undergone clinical trials in many countries, but the third phase of clinical data has not been submitted for publication in medical journals.

(Associated Press)

A government spokesman said on Wednesday (February 3) that the Department of Health has been actively following up with Kexing Holdings in order to obtain the third phase clinical study data of its new crown vaccine as soon as possible, and confirm that it meets the safety, efficacy and quality requirements and can be recognized as Emergency use.

And Kexing has stated to the government that it is preparing relevant information and will submit it to the Department of Health as soon as possible.

"Hong Kong 01" received news earlier that Kexing had already submitted information and application documents to relevant departments of the Department of Health at the end of January, and is awaiting review.

However, it is said that representatives of the Department of Health said that Kexing’s information was incomplete and would not be accepted.

Insiders familiar with the vaccine approval process explained today that the Department of Health did not reject the existing submissions of Kexing, and emphasized that the contract signed between Kexing and the government stated that the third phase of clinical data on the new crown vaccine must be in the medical journal Published.

The source also said that Kexing has agreed to provide the data to the WHO for approval by the expert committee of the Hong Kong government and arrange for the research and development experts of the vaccine factory to communicate with the government expert committee.

▼ Kexing vaccine needs seven steps from the laboratory to the market▼

+9

+9

+9

Chief Executive Carrie Lam Cheng Yuet-ngor had earlier appointed a committee of vaccine advisory experts to review information about the new crown vaccine.

The Secretary for Food and Health will consider the advice of the Advisory Expert Committee before approving the approved vaccine for emergency use.

When the expert committee meets depends on whether Kexing's data is available.

New Crown Vaccine｜Chen Zhaoshi: Part of the data that Kexing has submitted will meet as soon as the third report is available

New crown vaccine | China Kexing vaccine raw materials arrive in Brazil to produce 8.6 million doses

01 News | The internal information of Kexingjiao vaccine data reveals that the government has not "received goods" and the political circles criticize bureaucrats

01News

New crown pneumonia new crown vaccine China Kexing